Take a look at our previous reports:

H1 Report 2024
View Report
Annual Report 2023
View Report
H1 Report 2023
View Report
Annual Report 2022
View Report

Annual Report 2024

Twitter
LinkedIn

English
Dutch

English
Dutch

Home
At a Glance
Platforms and Portfolio
- Cell Therapies and Small Molecules
- R&D Pipeline in Oncology and Immunology
  - Oncology
  - Immunology
    - Jyseleca® Franchise
    - TYK2 Program: GLPG3667
Sustainability Statements
Corporate Governance
Risk Management
Financial Statements
Auditor's Report
- Report of the Statutory Auditor
- Report of the Statutory Auditor
  (Sustainability Statements)

At a Glance
Platforms and Portfolio
- Cell Therapies and Small Molecules
- R&D Pipeline in Oncology and Immunology
  - Oncology
    
    GLPG5101: CD19 CAR-T in R/R NHL
    
    GLPG5201: CD19 CAR-T in R/R CLL and RT
    
    GLPG5301: BCMA CAR-T in R/R MM
    
    Uza-cel
    
    Next-generation Programs
  - Immunology
    
    Jyseleca® Franchise
    
    TYK2 Program: GLPG3667
Sustainability Statements
Corporate Governance
Risk Management
Financial Statements
Auditor's Report
- Report of the Statutory Auditor
- Report of the Statutory Auditor
  (Sustainability Statements)

Downloads

Corporate Governance

Home
Corporate Governance
Remuneration Report
Severance Payments

Severance Payments

No severance payments were made in 2024 as no Executive Committee members left Galapagos.

Downloads

Financial Calendar

Glossary of Terms

next page
previous page

Galapagos Annual Report 2024 (PDF) Download PDF (13.9MB)

© Copyright 2025 Galapagos NV

Other Information
Contact
Privacy Notice
Forward-looking Statements

Downloads
Glossary of Terms